Illumina, Inc. (NASDAQ: ILMN) has secured the FDA’s approval for its in vitro diagnostic (IVD) TruSight Oncology Comprehensive test and first two companion diagnostic (CDx) indications. The test analyses more than 500 genes to profile a patient’s solid tumor, improving the chances of identifying an immuno-oncology or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. The latest development marks a long-awaited milestone for the company’s oncology customers and community. In Europe, a separate CE-marked version of TSO Comprehensive has been avail…